CA2699411A1 - Neuroendocrine factors for treatment of degenerative diseases - Google Patents

Neuroendocrine factors for treatment of degenerative diseases Download PDF

Info

Publication number
CA2699411A1
CA2699411A1 CA2699411A CA2699411A CA2699411A1 CA 2699411 A1 CA2699411 A1 CA 2699411A1 CA 2699411 A CA2699411 A CA 2699411A CA 2699411 A CA2699411 A CA 2699411A CA 2699411 A1 CA2699411 A1 CA 2699411A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
repellent factor
treatment
prevention
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2699411A
Other languages
English (en)
French (fr)
Inventor
Anja Bosserhoff
Thomas Schubert
Elisabeth Hustert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Formycon AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Individual filed Critical Individual
Publication of CA2699411A1 publication Critical patent/CA2699411A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2699411A 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases Abandoned CA2699411A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP07018131.8 2007-09-14
EP08006810 2008-04-03
EP08006810.9 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (1)

Publication Number Publication Date
CA2699411A1 true CA2699411A1 (en) 2009-03-19

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699411A Abandoned CA2699411A1 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Country Status (13)

Country Link
US (1) US20110002972A1 (enExample)
EP (1) EP2212344B1 (enExample)
JP (1) JP2010539123A (enExample)
KR (1) KR20100075493A (enExample)
CN (1) CN101821283A (enExample)
AU (1) AU2008297889A1 (enExample)
BR (1) BRPI0816784A8 (enExample)
CA (1) CA2699411A1 (enExample)
MX (1) MX2010002716A (enExample)
NZ (1) NZ583851A (enExample)
RU (1) RU2496790C2 (enExample)
WO (1) WO2009033715A2 (enExample)
ZA (1) ZA201001644B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
PH12013501205A1 (en) * 2010-12-23 2013-07-29 Sanofi Sa Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
ES3013463T3 (en) * 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
KR101617497B1 (ko) * 2012-06-15 2016-05-03 재단법인 아산사회복지재단 Slit3의 lrr2 유전자 또는 그 발현 단백질을 유효성분으로 함유하는 골절 또는 골다공증 예방 또는 치료용 약학적 조성물
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
JPWO2015072527A1 (ja) * 2013-11-13 2017-03-16 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
EP3116521B1 (en) * 2014-03-14 2024-07-31 The Research Foundation for The State University of New York Neurogenic regulation of bone growth and bone degradation
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
AU2020346062A1 (en) * 2019-09-13 2022-03-24 Rutgers, The State University Of New Jersey AAV-compatible laminin-linker polymerization proteins
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
JPWO2023008337A1 (enExample) * 2021-07-26 2023-02-02

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1203999A (en) * 1997-10-31 1999-05-24 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
AU3755100A (en) * 1999-03-17 2000-10-04 Washington University Vertebrate slit dna sequence, protein and uses thereof
AU2001278655A1 (en) * 2000-07-18 2002-01-30 Compugen Ltd. Novel nucleic acid and amino acid sequences
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
AU2001286446A1 (en) * 2000-08-10 2002-02-18 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
CN101600451A (zh) * 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法

Also Published As

Publication number Publication date
RU2010114713A (ru) 2011-10-20
BRPI0816784A8 (pt) 2016-01-19
US20110002972A1 (en) 2011-01-06
WO2009033715A3 (en) 2010-03-18
CN101821283A (zh) 2010-09-01
RU2496790C2 (ru) 2013-10-27
BRPI0816784A2 (pt) 2015-03-24
AU2008297889A1 (en) 2009-03-19
KR20100075493A (ko) 2010-07-02
EP2212344A2 (en) 2010-08-04
ZA201001644B (en) 2011-03-30
EP2212344B1 (en) 2014-03-26
JP2010539123A (ja) 2010-12-16
NZ583851A (en) 2012-06-29
MX2010002716A (es) 2010-07-05
WO2009033715A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
CA2699411A1 (en) Neuroendocrine factors for treatment of degenerative diseases
US10519213B2 (en) Fusion proteins of collagen-binding domain and parathyroid hormone
Beck et al. Structure and function of laminin: anatomy of a multidomain glycoprotein
EP0723588B1 (en) Activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family
EP2370463B1 (en) A stabilized variant of activin iib receptor
US7163920B2 (en) Peptide with osteogenic activity
US6632790B1 (en) Laminin 2 and methods for its use
TW200846359A (en) Variant activin receptor polypeptides and uses thereof
CN113347990A (zh) 膜联蛋白在预防和治疗肌膜损伤中的用途
US20250345393A1 (en) Isoform nell-1 peptide
EP1006126B1 (en) Osteogenic peptides
MXPA03010531A (es) Uso terapeutico de antagonistas de rank.
Duan et al. Experimental research on ectopic osteogenesis of BMP2-derived peptide P24 combined with PLGA copolymers
WO2011147320A1 (zh) B细胞激活因子拮抗剂及其制备方法与用途
US10130687B2 (en) Compositions and methods for the treatment of orthopedic disease or injury
EP2036921A1 (en) Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
JP5484648B2 (ja) 骨の石灰化促進因子

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140912